A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database

References

• Musa IH, Afolabi LO, Zamit I, Musa TH, Musa HH, Tassang A, Akintunde TY, Li W. Artificial intelligence and machine learning in cancer research : a systematic and thematic analysis of the top 100 cited articles indexed in Scopus database. Cancer Control. 2022;29. doi:10.1177/10732748221095946.
   PubMed Web of Science ®Google Scholar
• Biggs PM. Gordon memorial lecture. Vaccines and vaccination–past, present and future. Br Poult Sci. 1990;31:1–24. doi:10.1080/00071669008417226.
   Google Scholar
• Cai X, Li JJ, Liu T, Brian O, Li J. Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design. Brief Funct Genomics. 2021;20:289–303. doi:10.1093/bfgp/elab027.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–79. doi:10.1038/nrd.2017.243.
   PubMed Web of Science ®Google Scholar
• Bettini E, Locci M. SARS-CoV-2 mRNA Vaccines: immunological mechanism and beyond. Vaccines. 2021;9:147. doi:10.3390/vaccines9020147.
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20:817–38. doi:10.1038/s41573-021-00283-5.
   PubMed Web of Science ®Google Scholar
• Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet (London, England). 2017;390:1511–20. doi:10.1016/S0140-6736(17)31665-3.
   PubMed Web of Science ®Google Scholar
• Casadevall A. The mRNA vaccine revolution is the dividend from decades of basic science research. J Clin Invest. 2021:131. doi:10.1172/JCI153721.
   Web of Science ®Google Scholar
• Freyn AW, Ramos da Silva J, Rosado VC, Bliss CM, Pine M, Mui BL, Tam YK, Madden TD, de Souza Ferreira LC, Weissman D, et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol Ther. 2020;28:1569–84. doi:10.1016/j.ymthe.2020.04.018.
   PubMed Web of Science ®Google Scholar
• Wu K, Choi A, Koch M, Elbashir S, Ma L, Lee D, Woods A, Henry C, Palandjian C, Hill A, et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine. 51;39: 7394–7400 . 2021.
   Google Scholar
• Sandbrink JB, Shattock RJ. RNA vaccines: a suitable platform for tackling emerging pandemics? Front Immunol. 2020;11:608460. doi:10.3389/fimmu.2020.608460.
   PubMed Web of Science ®Google Scholar
• Akintunde TY, Musa TH, Musa HH, Musa IH, Shaojun C, Ibrahim E, Tassang AE, MSEDM H. Bibliometric analysis of global scientific literature on effects of COVID-19 pandemic on mental health. Asian J Psychiatr. 2021;63:102753. doi:10.1016/j.ajp.2021.102753.
   PubMed Web of Science ®Google Scholar
• Musa IH, Musa TH, Zamit I, Okeke M. Artificial intelligence and machine learning in oncology: historical overview of documents indexed in the web of science database. Eurasian J Med Oncol. 2021;5:239–48. doi:10.14744/ejmo.2021.24856.
   Google Scholar
• Kawuki J, Ghimire U, Papabathini SS, Obore N, Musa TH. A bibliometric analysis of childhood obesity research from China indexed in Web of Science. J Public Heal Emerg. 2021;5:3. doi:10.21037/jphe-20-95.
   Google Scholar
• Musa TH, Ahmad T, Li W, Kawuki J, Wana MN, Musa HH, Wei P. A bibliometric analysis of global scientific research on Scrub Typhus. Biomed Res Int. 2020;2020:1–9. doi:10.1155/2020/5737893.
   Web of Science ®Google Scholar
• Musa TH, Li W, Kawuki J, Wei P. The 100 top-cited articles on scrub typhus : a bibliometric analysis. Osong Public Health Res Perspect. 2021;12:126–35. doi:10.24171/j.phrp.2021.12.2.10.
   PubMedGoogle Scholar
• Akintunde TY, Musa TH, Musa HH, Ibrahim E, Muhideen S, Kawuki J. Mapping the global research output on Ebola vaccine from research indexed in web of science and Scopus : a comprehensive bibliometric analysis. Hum Vaccin Immunother. 2021;00:1–13. doi:10.1080/21645515.2021.1948785.
   Google Scholar
• Musa HH, El-Sharief M, Musa IH, Musa TH, Akintunde TY. Global scientific research output on sickle cell disease : a comprehensive bibliometric analysis of web of science publication. Sci African. 2021;12:e00774. doi:10.1016/j.sciaf.2021.e00774.
   Google Scholar
• Gatasi G, Musa TH, Odjidja EN. Bibliometric analysis of the top 100 cited articles on HIV/AIDS. Ann Infect. 2021;5:6. doi:10.21037/aoi-20-17.
   Google Scholar
• Akintunde TY, Chen S, Musa TH, Amoo FO, Adedeji A, Ibrahim E, Tassang AE, Musa IH, Musa HH. Tracking the progress in COVID-19 and vaccine safety research - a comprehensive bibliometric analysis of publications indexed in Scopus database. Hum Vaccin Immunother. 2021;17:3887–97. doi:10.1080/21645515.2021.1969851.
   PubMed Web of Science ®Google Scholar
• Kawuki J, Yu X, Musa TH. Bibliometric analysis of Ebola research indexed in web of science and Scopus (2010-2020). Biomed Res Int. 2020;2020:1–12. doi:10.1155/2020/5476567.
   Web of Science ®Google Scholar
• Musa TH, Akintunde TY, Musa HH, Ghimire U, Gatasi G. Malnutrition research output : a bibliometric analysis for articles index in web of science between 1900 and 2020. Electron J Gen Med. 2021;18:em293. doi:10.29333/ejgm/10840.
   Web of Science ®Google Scholar
• Sharun K, Musa TH, Musa HH, Kumar R, Pawde AM, Chandra V, Tuli HS, Dhama K, Sharma GT. Mapping global trends in adipose-derived mesenchymal stem cell research: a bibliometric analysis using Scopus database. Ann Med Surg. 2022;77:103542. https://www.sciencedirect.com/science/article/pii/S2049080122003028.
   PubMed Web of Science ®Google Scholar
• Musa TH, Akintunde TY, Musa IH, Mohammed LA, Tassang AE, Musa HH. Rift valley fever: thematic analysis of documents indexed in the web of science core collection database. Ann Infect. 2022;6:1. doi:10.21037/aoi-21-9.
   Google Scholar
• Kawuki J, Musa TH, Papabathini SS, Ghimire U, Obore N, Yu X. The 100 top-cited studies on Ebola: a bibliometric analysis. Electron J Gen Med. 2021;18:em276. doi:10.29333/ejgm/9694.
   Web of Science ®Google Scholar
• Dervis H. Bibliometric analysis using bibliometrix an R package. J Scientometr Res. 2019;8:156–60. doi:10.5530/jscires.8.3.32.
   Web of Science ®Google Scholar
• Van Eck NJ, Waltman L. Vosviewer Manual version 1.6.10. CWTS Meaningful Metrics . 2019;1–53.
   Google Scholar
• Chen C, Sanjuan FI, Hou J. The structure and dynamics of co ‐ citation clusters : a multiple ‐ perspective co ‐ citation analysis. J Am Soc Inf Science Technol. 2010;61(7):1386–409. doi:10.1002/asi.21309.
   Web of Science ®Google Scholar
• Moral-Muñoz JA, Herrera-Viedma E, Santisteban-Espejo A, Cobo MJ. Software tools for conducting bibliometric analysis in science: an up-to-date review. El Profesional de la Información. 2020;29. doi:10.3145/epi.2020.ene.03.
   Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med. 2020;383:1920–31. doi:10.1056/NEJMoa2022483.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD. Bnt162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–23. doi:10.1056/NEJMoa2101765.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427–38. doi:10.1056/NEJMoa2028436.
   PubMed Web of Science ®Google Scholar
• Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616–22. doi:10.1038/s41586-021-03324-6.
   PubMed Web of Science ®Google Scholar
• Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet (London, England). 2021;397:1819–29. doi:10.1016/S0140-6736(21)00947-8.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O’Connell S, Bock KW, Minai M, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383:1544–55. doi:10.1056/NEJMoa2024671.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–71. doi:10.1038/s41586-020-2622-0.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543:248–51. doi:10.1038/nature21428.
   PubMed Web of Science ®Google Scholar
• Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168:1114–25.e10. doi:10.1016/j.cell.2017.02.017.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, Frankland TB, Ogun OA, Zamparo JM, Gray S, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet (London, England). 2021;398:1407–16. doi:10.1016/S0140-6736(21)02183-8.
   PubMed Web of Science ®Google Scholar
• Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5’ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine. Proc Natl Acad Sci U S A. 1995;92:11563–67. doi:10.1073/pnas.92.25.11563.
   PubMed Web of Science ®Google Scholar
• Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593:136–41. doi:10.1038/s41586-021-03412-7.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Moreira EDJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385:1761–73. doi:10.1056/NEJMoa2110345.
   PubMed Web of Science ®Google Scholar
• Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, Marquez PL, Olson CK, Liu R, Chang KT, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384:2373–82. https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106349611&doi=10.1056%2FNEJMoa2104983&partnerID=40&md5=b06b3188e964e1dc834988c23a9cc7db.
   Web of Science ®Google Scholar
• Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, Olsho LEW, Caban-Martinez AJ, Fowlkes A, Lutrick K, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - Eight U.S. Locations, December 2020-March. Morbid Mortality Weekly Rep. 2021;70:495–500. doi:10.15585/mmwr.mm7013e3.
   PubMed Web of Science ®Google Scholar
• Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397:1725–35. doi:10.1016/S0140-6736(21)00790-X.
   PubMed Web of Science ®Google Scholar
• Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, Laska ME, Smith M, Almarsson Ö, Thompson J, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25:1316–27. doi:10.1016/j.ymthe.2017.03.035.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales M, Ziv T, Shorer Arbel Y, Scarfò L, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–73. doi:10.1182/blood.2021011568.
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernán MA, Lipsitch M, Kohane I, Netzer D, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385:1078–90. doi:10.1056/NEJMoa2110475.
   PubMed Web of Science ®Google Scholar
• Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen K-J, Stitz L, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza a virus infection. Nat Biotechnol. 2012;30:1210–16. doi:10.1038/nbt.2436.
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, Reis BY, Balicer RD. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet (London, England). 2021;398:2093–100. doi:10.1016/S0140-6736(21)02249-2.
   PubMed Web of Science ®Google Scholar
• Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, Frias EC, Stewart JL, Van Eyk JE, Braun JG, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27:981–84. doi:10.1038/s41591-021-01325-6.
   PubMed Web of Science ®Google Scholar
• Zhang N-N, X-F L, Deng Y-Q, Zhao H, Huang Y-J, Yang G, Huang W-J, Gao P, Zhou C, Zhang R-R, et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020;182:1271–83.e16. doi:10.1016/j.cell.2020.07.024.
   PubMed Web of Science ®Google Scholar
• Reichmuth AM, Oberli MA, Jeklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7:319–34. doi:10.4155/tde-2016-0006.
   PubMed Web of Science ®Google Scholar
• Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, Gouma S, Hicks P, Meng W, Rosenfeld AM, et al. Distinct antibody and memory B cell responses in SARSCoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol. 2021;6:1–19. https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104447408&doi=10.1126%2Fsciimmunol.abi6950&partnerID=40&md5=3f8771d9ed789e8df10d7e4d6e56492c.
   Web of Science ®Google Scholar
• Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee H-G, Garbe C. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother (1991). 2009;32:498–507. doi:10.1097/CJI.0b013e3181a00068.
   PubMed Web of Science ®Google Scholar
• Turner JS, O’Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, Lei T, Thapa M, Chen RE, Case JB, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021;596:109–13. doi:10.1038/s41586-021-03738-2.
   PubMed Web of Science ®Google Scholar
• Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, Neradilek M, Seydoux E, Jennewein MF, MacCamy AJ, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372:1413–18. doi:10.1126/science.abg9175.
   PubMed Web of Science ®Google Scholar
• Ryan M, Montgomery J, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrncir D, Herring K, Platzer M, et al. Myocarditis following immunization with mrna covid-19 vaccines in members of the us military. JAMA Cardiol. 2021;6:1202–06. doi:10.1001/jamacardio.2021.2833.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Willis E, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215:1571–88. doi:10.1084/jem.20171450.
   PubMed Web of Science ®Google Scholar
• Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Meidan R, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80:1330–38. doi:10.1136/annrheumdis-2021-220647.
   PubMed Web of Science ®Google Scholar
• Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A, Yuzhakov O, Himansu S, Deterling J, Geilich BM, Ketova T, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther - Nucleic Acids. 2019;15:1–11. doi:10.1016/j.omtn.2019.01.013.
   Google Scholar
• Miao L, Li L, Huang Y, Delcassian D, Chahal J, Han J, Shi Y, Sadtler K, Gao W, Lin J, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019;37:1174–85. doi:10.1038/s41587-019-0247-3.
   PubMed Web of Science ®Google Scholar
• Feldman RA, Fuhr R, Smolenov I, Ribeiro AM, Panther L, Watson M, Senn JJ, Smith M, Almarsson Ӧ, Pujar HS, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37:3326–34. doi:10.1016/j.vaccine.2019.04.074.
   PubMed Web of Science ®Google Scholar
• Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, Wicke L, Perkovic M, Beissert T, Haas H, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther. 2018;26:446–55. doi:10.1016/j.ymthe.2017.11.017.
   PubMed Web of Science ®Google Scholar
• Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, Reid HM, Schaffarzyk A, Longardt AC, Franzenburg J, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021;80:1306–11. doi:10.1136/annrheumdis-2021-220272.
   PubMed Web of Science ®Google Scholar
• Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, Olsho LEW, Caban-Martinez AJ, Fowlkes AL, Lutrick K, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385:320–29. doi:10.1056/NEJMoa2107058.
   PubMed Web of Science ®Google Scholar
• Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, Olsha-Castell S, Arad D, Hasin T, Levi N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385:2140–49. doi:10.1056/NEJMoa2109730.
   PubMed Web of Science ®Google Scholar
• Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EMI, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother. 2013;62:1499–509. doi:10.1007/s00262-013-1453-3.
   PubMed Web of Science ®Google Scholar
• Weide B, Carralot J-P, Reese A, Scheel B, Eigentler TK, Hoerr I, Rammensee H-G, Garbe C, Pascolo S. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother (1991). 2008;31:180–88. doi:10.1097/CJI.0b013e31815ce501.
   PubMed Web of Science ®Google Scholar
• Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M, Katchman E, Halperin T, Turner D, Goykhman Y, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021;21:2719–26. doi:10.1111/ajt.16615.
   PubMed Web of Science ®Google Scholar
• Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, Donahue JG, Kharbanda EO, Naleway A, Nelson JC, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326:1390–99. doi:10.1001/jama.2021.15072.
   PubMed Web of Science ®Google Scholar
• Liu X, Shaw RH, Stuart AS, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet (London, England). 2021;398:856–69. doi:10.1016/S0140-6736(21)01694-9.
   PubMed Web of Science ®Google Scholar
• Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14. doi:10.1177/17562864211012835
   Web of Science ®Google Scholar
• Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, Lundgreen KA, Reynaldi A, Khoury DS, Pattekar A, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374:abm0829. doi:10.1126/science.abm0829.
   PubMed Web of Science ®Google Scholar
• Pegu A, O’Connell SE, Schmidt SD, O’Dell S, Talana CA, Lai L, Albert J, Anderson E, Bennett H, Corbett KS, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021;373:1372–77. doi:10.1126/science.abj4176.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang Y, Miao L, Liu Q, Musetti S, Li J, Huang L. Combination immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer. Mol Ther. 2018;26:45–55. doi:10.1016/j.ymthe.2017.10.020.
   PubMed Web of Science ®Google Scholar
• Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Rezk A, Patterson KR, Espinoza DA, Kadri JC, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27:1990–2001. doi:10.1038/s41591-021-01507-2.
   PubMed Web of Science ®Google Scholar
• Collier A-R, McMahan K, Yu J, Tostanoski LH, Aguayo R, Ansel J, Chandrashekar A, Patel S, Apraku Bondzie E, Sellers D, et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. J Am Med Assoc. 2021;325:2370–80. doi:10.1001/jama.2021.7563.
   PubMed Web of Science ®Google Scholar
• Pollard C, Rejman J, De Haes W, Verrier B, Van Gulck E, Naessens T, De Smedt S, Bogaert P, Grooten J, Vanham G, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. 2013;21:251–59. doi:10.1038/mt.2012.202.
   PubMed Web of Science ®Google Scholar
• Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, Edelstein M. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Eurosurveillance. 2021;26:2100096. doi:10.2807/1560-7917.ES.2021.26.6.2100096.
   Web of Science ®Google Scholar
• Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, Malek JA, Coyle P, Ayoub HH, Al Kanaani Z, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021;27:1614–21. doi:10.1038/s41591-021-01446-y.
   PubMed Web of Science ®Google Scholar
• Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer. 2015;3:26. doi:10.1186/s40425-015-0068-y.
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385:1774–85. doi:10.1056/NEJMoa2113017.
   PubMed Web of Science ®Google Scholar
• Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, Haddad A, Elias M, Zisman D, Naffaa ME, et al. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines. 2021;9:435. doi:10.3390/vaccines9050435.
   PubMed Web of Science ®Google Scholar
• Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, Castaño D, Amanat F, Muramatsu H, Oguin TH, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. 2020;53:724–32.e7. doi:10.1016/j.immuni.2020.07.019.
   PubMed Web of Science ®Google Scholar
• Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, Abu-Omar A, Ziegler L, Guckelmus C, Urschel R, et al. Immunogenicity and reactogenicity of heterologous ChAdox1 nCov-19/mrna vaccination. Nat Med. 2021;27:1530–35. doi:10.1038/s41591-021-01464-w.
   PubMed Web of Science ®Google Scholar
• Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, John S, Hassett K, Yuzhakov O, Bahl K, et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in Rhesus Macaques. Mol Ther. 2017;25:2635–47. doi:10.1016/j.ymthe.2017.08.006.
   PubMed Web of Science ®Google Scholar
• Bonehill A, Van Nuffel AMT, Corthals J, Tuyaerts S, Heirman C, François V, Colau D, van der Bruggen P, Neyns B, Thielemans K. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res. 2009;15:3366–75. doi:10.1158/1078-0432.CCR-08-2982.
   PubMed Web of Science ®Google Scholar
• Lederer K, Castaño D, Gómez Atria D, Oguin TH, Wang S, Manzoni TB, Muramatsu H, Hogan MJ, Amanat F, Cherubin P, et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. Immunity. 2020;53:1281–95.e5. doi:10.1016/j.immuni.2020.11.009.
   PubMed Web of Science ®Google Scholar
• Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, AlMukdad S, Coyle P, Ayoub HH, Al Kanaani Z, et al. Bnt162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27:2136–43. doi:10.1038/s41591-021-01583-4.
   PubMed Web of Science ®Google Scholar
• Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, Nunna N, Huang W, Oestreicher J, Colpitts T, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021;27:2025–31. doi:10.1038/s41591-021-01527-y.
   PubMed Web of Science ®Google Scholar
• Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA, Lundberg R, Maljanen S, Reinholm A, Tauriainen S, Pakkanen SH, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021;12. doi:10.1038/s41467-021-24285-4.
   Web of Science ®Google Scholar
• Stumpf J, Siepmann T, Lindner T, Karger C, Schwöbel J, Anders L, Faulhaber-Walter R, Schewe J, Martin H, Schirutschke H, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Heal - Eur. 2021;9:100178. doi:10.1016/j.lanepe.2021.100178.
   PubMedGoogle Scholar
• Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, Baxter AE, Herati RS, Oldridge DA, Gouma S, et al. Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021;54:2133–42.e3. doi:10.1016/j.immuni.2021.08.001.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, Ghamande S, Douin DJ, Talbot HK, Casey JD, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326:2043–54. doi:10.1001/jama.2021.19499.
   PubMed Web of Science ®Google Scholar
• Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. 2021;110:997–1001. doi:10.1016/j.xphs.2020.12.006.
   PubMed Web of Science ®Google Scholar
• Kim HW, Jenista ER, Wendell DC, Azevedo CF, Campbell MJ, Darty SN, Parker MA, Kim RJ. Patients with acute myocarditis following mRNA COVID-19 vaccination. JAMA Cardiol. 2021;6:1196–201. doi:10.1001/jamacardio.2021.2828.
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Van Nuffel AMT, Corthals J, Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I, Verfaillie G, Vandeloo J, et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother (1991). 2011;34:448–56. doi:10.1097/CJI.0b013e31821dcb31.
   PubMed Web of Science ®Google Scholar
• Cucchiari D, Egri N, Bodro M, Herrera S, Del Risco-Zevallos J, Casals-Urquiza J, Cofan F, Moreno A, Rovira J, Banon-Maneus E, et al. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021;21:2727–39. doi:10.1111/ajt.16701.
   PubMed Web of Science ®Google Scholar
• Abu Mouch S, Roguin A, Hellou E, Ishai A, Shoshan U, Mahamid L, Zoabi M, Aisman M, Goldschmid N, Berar Yanay N. Myocarditis following COVID-19 mRNA vaccination. Vaccine. 2021;39:3790–93. doi:10.1016/j.vaccine.2021.05.087.
   PubMed Web of Science ®Google Scholar
• Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, Akilli-Öztürk Ö, Kranz LM, Berger H, Petschenka J, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021;371:145–53. doi:10.1126/science.aay3638.
   PubMed Web of Science ®Google Scholar
• Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, Naumovas D, Banys V, Pečeliūnas V, Beinortas T, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8:e583–92. doi:10.1016/S2352-3026(21)00169-1.
   PubMed Web of Science ®Google Scholar
• Carralot J-P, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, Rammensee H-G, Pascolo S. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci. 2004;61:2418–24. doi:10.1007/s00018-004-4255-0.
   PubMed Web of Science ®Google Scholar
• Verbeke R, Lentacker I, De Smedt SC, Dewitte H. The dawn of mRNA vaccines: the COVID-19 case. J Control Release. 2021;333:511–20. doi:10.1016/j.jconrel.2021.03.043.
   PubMed Web of Science ®Google Scholar
• Mockey M, Bourseau E, Chandrashekhar V, Chaudhuri A, Lafosse S, Le Cam E, Quesniaux VFJ, Ryffel B, Pichon C, Midoux P. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 2007;14:802–14. doi:10.1038/sj.cgt.7701072.
   PubMed Web of Science ®Google Scholar
• Lutz J, Lazzaro S, Habbeddine M, Schmidt KE, Baumhof P, Mui BL, Tam YK, Madden TD, Hope MJ, Heidenreich R, et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines. 2017;2:29. doi:10.1038/s41541-017-0032-6.
   PubMed Web of Science ®Google Scholar
• Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M, Koralov SB, Atreya R, Tascilar K, Allen JR, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80:1339–44. doi:10.1136/annrheumdis-2021-220597.
   PubMed Web of Science ®Google Scholar
• Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, El-Qunni AA, Haile A, Huang K, Kinnett B, et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2 : a prospective cohort study. Ann Intern Med. 2021;174:1572–85. doi:10.7326/M21-1757.
   PubMed Web of Science ®Google Scholar
• Pascolo S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol. 2008;183:221–35.
   PubMedGoogle Scholar
• Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376–81. doi:10.1016/j.ijid.2021.04.047.
   PubMed Web of Science ®Google Scholar
• Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, Ding B, Dooley J, Girard B, Hillebrand W, et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med. 2021;385:2241–51. doi:10.1056/NEJMoa2109522.
   PubMed Web of Science ®Google Scholar
• Rozen-Zvi B, Yahav D, Agur T, Zingerman B, Ben-Zvi H, Atamna A, Tau N, Mashraki T, Nesher E, Rahamimov R. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect. 2021;27:e1173.1–34. doi:10.1016/j.cmi.2021.04.028.
   Web of Science ®Google Scholar
• Brazzoli M, Magini D, Bonci A, Buccato S, Giovani C, Kratzer R, Zurli V, Mangiavacchi S, Casini D, Brito LM, et al. Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J Virol. 2016;90:332–44. doi:10.1128/JVI.01786-15.
   PubMed Web of Science ®Google Scholar
• Hobo W, Novobrantseva TI, Fredrix H, Wong J, Milstein S, Epstein-Barash H, Liu J, Schaap N, van der Voort R, Dolstra H. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother. 2013;62:285–97. doi:10.1007/s00262-012-1334-1.
   PubMed Web of Science ®Google Scholar
• Li M, Zhao M, Fu Y, Li Y, Gong T, Zhang Z, Sun X. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- a nd paracellular pathways. J Control Release. 2016;228:9–19. doi:10.1016/j.jconrel.2016.02.043.
   PubMed Web of Science ®Google Scholar
• Schnee M, Vogel AB, Voss D, Petsch B, Baumhof P, Kramps T, Stitz L. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis. 2016;10:e0004746. doi:10.1371/journal.pntd.0004746.
   PubMed Web of Science ®Google Scholar
• Oberhardt V, Luxenburger H, Kemming J, Schulien I, Ciminski K, Giese S, Csernalabics B, Lang-Meli J, Janowska I, Staniek J, et al. Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. Nature. 2021;597:268–73. doi:10.1038/s41586-021-03841-4.
   PubMed Web of Science ®Google Scholar
• Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, Leav B. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021;39:2791–99. doi:10.1016/j.vaccine.2021.02.007.
   PubMed Web of Science ®Google Scholar
• Zhou WZ, Hoon DS, Huang SK, Fujii S, Hashimoto K, Morishita R, Kaneda Y. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Hum Gene Ther. 1999;10:2719–24. doi:10.1089/10430349950016762.
   PubMed Web of Science ®Google Scholar
• John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw CA, Ciaramella G. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018;36:1689–99. doi:10.1016/j.vaccine.2018.01.029.
   PubMed Web of Science ®Google Scholar
• Brito LA, Kommareddy S, Maione D, Uematsu Y, Giovani C, Berlanda Scorza F, Otten GR, Yu D, Mandl CW, Mason PW, et al. Self-Amplifying mRNA Vaccines. Adv Genet. 2015;89:179–233.
   PubMed Web of Science ®Google Scholar
• Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, Chen B, Calzavara A, Fell DB, Austin PC, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. 2021;374:n1943.
   PubMedGoogle Scholar
• Moor MB, Suter-Riniker F, Horn MP, Aeberli D, Amsler J, Möller B, Njue LM, Medri C, Angelillo-Scherrer A, Borradori L, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;3:e789–97. doi:10.1016/S2665-9913(21)00251-4.
   PubMedGoogle Scholar
• Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Laroni A, Lapucci C, Da Rin G, Serrati C, Gandoglia I, Tassinari T, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021;72:103581. doi:10.1016/j.ebiom.2021.103581.
   PubMed Web of Science ®Google Scholar
• Amanat F, Thapa M, Lei T, Ahmed SMS, Adelsberg DC, Carreño JM, Strohmeier S, Schmitz AJ, Zafar S, Zhou JQ, et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021;184:3936–48.e10. doi:10.1016/j.cell.2021.06.005.
   PubMed Web of Science ®Google Scholar
• Shebl FM, Pinto LA, García-Piñeres A, Lempicki R, Williams M, Harro C, Hildesheim A. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol Biomarkers Prevent. 2010;19:978–81. doi:10.1158/1055-9965.EPI-10-0064.
   PubMed Web of Science ®Google Scholar
• Friedman A. The power of Lotka’ s Law through the eyes of R Romanian Statistical Review. 2015;63: 69–77.
   Google Scholar
• Pao ML. Lotka’s law: a testing procedure. Inf Process Manag. 1985;21:305–20. https://www.sciencedirect.com/science/article/pii/030645738590055X.
   Web of Science ®Google Scholar
• Sen BK. Lotka’s Law: a viewpoint. Ann Libr Inf Stud. 2010;57:166–68.
   Google Scholar